Solara Active Pharma Sciences shared the Q2 FY26 earnings call transcript, detailing a major upgrade at the Mangalore facility (INR 4-5 crore), a temporary August shutdown, FDA clearance with two minor observations, and guidance indicating a cost base near INR 117-120 crores.